(MedPage Today) — The FDA extended its decision date for investigational tolebrutinib in non-relapsing, secondary progressive multiple sclerosis (MS) to December 28, Sanofi said.
The agency also opted to not approve investigational apitegromab…
Source link : https://www.medpagetoday.com/neurology/generalneurology/117608
Author :
Publish date : 2025-09-23 18:26:00
Copyright for syndicated content belongs to the linked Source.
